Organization (Academic)
Pontifícia Universidade Católica do Rio Grande do Sul
ClinicalTrials.gov lists Pontifícia Universidade Católica do Rio Grande do Sul as lead sponsor of 22 trials. It has 3 active development programs and 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.
Logo Phillipegarcia, via Wikimedia Commons, CC BY-SA 3.0. Shown to identify the organization; it may be a registered trademark.
This page covers Pontifícia Universidade Católica do Rio Grande do Sul: 22 lead-sponsored trials and 1 legal-entity registration.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (30)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Anxiety Disorders | 2 |
| Diabetes Mellitus | 2 |
| Frailty | 2 |
| Multiple Sclerosis | 2 |
| Obesity | 2 |
Showing 5 of 30 disease areas.
Trials by start year as sponsor or collaborator (13)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 4 |
| 2018 | 3 |
| 2017 | 3 |
| 2016 | 2 |
| 2015 | 2 |
Showing 10 of 13 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (3)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Oxytocin Nasal Spray (48 IU) | Substance-Related Disorders | Phase 1/2 | 1 |
| Oxytocin Nasal Spray (48 IU) | Cocaine-Related Disorders | Phase 1/2 | 1 |
| Intervention Group | Frailty | Not reported | 1 |
Approved assets (1)
| Drug | Trials |
|---|---|
| Cladribine 10 mg oral tablet | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 64% hit target (n=11) | 45% on time (n=11) |
Journals published in (78)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The European respiratory journal | 4 |
| Chest | 3 |
| Journal of bodywork and movement therapies | 3 |
| Journal of clinical periodontology | 3 |
| Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society | 3 |
Showing 5 of 78 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1 | 0 | 2016-05-24 |
Organization relationships (5)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Universidade Federal da Bahia | Co sponsors trial with | 1 |
| Ministry of Science, Technology and Innovation | Co sponsors trial with | 1 |
| Hospital Universitário Professor Edgard Santos | Co sponsors trial with | 1 |
| Merck S.A., Brazil, an affiliate of Merck KGaA, Darmstadt, Germany | Co sponsors trial with | 1 |
| Teva Pharmaceuticals USA | Co sponsors trial with | 1 |
Latest dated events (28)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-12-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-05-28 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 28 events.
Biomarker capability evidence (2)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| DMD | Trial sponsor | Named in trial inclusion criteria |
| DMD | Trial sponsor | Mentioned in trial text |
Biomarkers this organization publishes on (78)
Shown in this order: most publications first.
Showing 5 of 78 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.